Development of an intranasal vaccine against gonorrhea based on outer membrane vesicles combined with sustained-release microspheres containing recombinant human interleukin-12.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93022C00058
- Awardee
-
Intravacc B.V. UEI RY3NEWMNZA63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,612,767
Award facts
- Opportunity
-
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases Pre-Solicitation · 20211 · Posted Feb 8, 2021
- Contract value 45% obligated
-
- $6,612,767.00 Current, with exercised options
- $14,613,141.00 Potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Netherlands
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,174,464 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,674,055 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $756,750 | |
| Other Administrative Action | $0 | |
| Original award | $2,007,498 |
Show all 11
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14.6 million cost-no-fee definitive contract to Netherlands-based Intravacc B.V. on September 21, 2022, to develop an intranasal vaccine against gonorrhea utilizing outer membrane vesicles combined with sustained-release microspheres containing recombinant human interleukin-12. The contract, which extends through December 2026, was issued under NIAID's Omnibus Broad Agency Announcement seeking advanced development of vaccine candidates against priority pathogens including antimicrobial resistant infections and emerging infectious diseases. No set-aside designation was applied to this award. Intravacc, a for-profit vaccine development company specializing in bridge services between discovery and pilot-scale biomanufacturing, will perform all work in the Netherlands.
This contract represents a continuation of NIAID's strategic investment in Intravacc's vaccine development capabilities, following a prior $9.4 million award in 2020 for development of an Enterovirus D68 vaccine candidate. The gonorrhea vaccine initiative aligns with NIAID's broader medical countermeasures program and responds to the public health priority of developing preventive solutions against sexually transmitted infections. Intravacc's selection reflects the company's established expertise in vaccine platform technologies and its prior successful collaboration with federal partners on related infectious disease vaccine programs.
Quick answers
Who was awarded contract 75N93022C00058?
75N93022C00058 was awarded to Intravacc B.V. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 21, 2022.
How much is contract 75N93022C00058 worth?
The government has obligated $6,612,767 on 75N93022C00058. Its potential value, with all options, is $14,613,141.
Was contract 75N93022C00058 competed?
The extent of competition for 75N93022C00058 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award